| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Valo | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $406.25M | Series B | 3/9/2021 | $310M | $919.92M | $5.88 | PSP Investments, Flagship Pioneering, Invus Public Equities, HBM Healthcare Investments, Atinum Investment, Mirae Asset Capital, Koch Disruptive Technologies | ||||
 | Vineti | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $107.72M | Series C | 10/13/2020 | $60M | $216.51M | $1.67 | Cardinal Health, Marc Benioff, Canaan Partners, Threshold Ventures, Section 32, Casdin Capital, Novartis Pharma AG, McKesson Ventures, LifeForce Capital, Hive Ventures | ||||
 | Well | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $183.32M | Series B-2 | 11/19/2025 | $30M | $486.14M | $16.00 | Undisclosed Investors | ||||
 | XtalPi | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | 3T Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | 4D Molecular Therapeutics (4DMT) | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | 98point6 | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $267.22M | Series E | 10/15/2020 | $134.21M | $548.43M | $6.59 | L Catterton, Activant Capital, Goldman Sachs | ||||
 | Alterome Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $231.07M | Series B | 4/3/2024 | $132M | $356.19M | $4.08 | Goldman Sachs Alternatives, Canaan Partners, Invus, Driehaus Capital Management, Digitalis Ventures, Blue Owl Capital, OrbiMed, Nextech Invest, Vida Ventures, Boxer Capital, Colt Ventures | ||||
 | Apogee Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Athelas | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $365.02M | Series B-2 | 10/3/2023 | $60M | $969.5M | $103.96 | Undisclosed Investors | ||||
 | Be Biopharma | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $274.72M | Series C | 1/15/2025 | $92.62M | $154.23M | $2.90 | ARCH Venture Partners, Atlas Venture, RA Capital Management, Alta Partners, Longwood Fund, Bristol Myers Squibb, Takeda Ventures, Nextech | ||||
 | Belief Biomed | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Bicara Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $710.05M | Series C | 12/12/2023 | $165M | $495.55M | $1.38 | Braidwell LP, TPG, The Rise Fund, Deerfield Management, Fairmount, Aisling Capital, Red Tree Venture Capital, RA Capital Management, F-Prime Capital, Eight Roads Ventures, Invus Piper Heartland Healthcare Capital, Premji Invest, Omega Funds, Bioqube Ventures, Acorn Bioventures, Janus Henderson Investors | ||||
 | Bolt Biotherapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Cellibre | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | CG Oncology | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $510.76M | Series F | 8/2/2023 | $105.02M | $615.24M | $1.29 | Foresite Capital, TCGX, Avidity Partners, BVF Partners, Janus Henderson Investors, Acorn Bioventures, Ally Bridge Group, Decheng Capital, Longitude Capital, Malin Corporatoin, RA Capital Management | ||||
 | ChromaCode | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Clario | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Clarus Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $109.16M | Series D | 6/12/2014 | $81.23M | $174.1M | $4.50 | Thomas McNerney & Partners, C-Bridge Capital, BVCF | ||||
 | Dispatch Biotherapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $179.79M | Series A | 7/23/2025 | $114M | $270.29M | $3.04 | ARCH Venture Partners, PICI, Bristol Myers Squibb, University of Pennsylvania, Stanford University, Alexandria Venture Investments | ||||
 | DispatchHealth | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.44B | Series A-1 | 4/30/2026 | $97.71M | $703.5M | $63.16 | Undisclosed Investors | ||||
 | Dragonfly Therapeutics | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Elation Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $229.44M | Series D | 7/26/2022 | $50M | $395.27M | $3.11 | Generation Investment Management, Ascension Ventures, Threshold Ventures, Ascend Partners, Fay Rotenberg, Jonathan Bush | ||||
 | Element Science | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $115.4M | Series C-3 | 3/3/2020 | $163.35 | $296.95M | $1.63 | Deerfield Healthcare, Qiming Venture Partners, Cormorant Asset Management, Invus Opportunities, Third Rock Ventures, GV | ||||